FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Amicus Therapeutics, Inc.

1 Cedar Brook Drive
Cranbury, NJ 08512
United States
609-662-2000
http://www.amicusrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees263

Key Executives

NameTitlePayExercisedAge
Mr. John F. Crowley1.72MN/A50
Mr. Bradley L. Campbell657.99kN/A41
Mr. William D. Baird III543.52k19.43k45
Dr. Hung Do Ph.D.502.32kN/A49
Dr. Jay A. Barth M.D.782.29kN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Corporate Governance

Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.